Drugs / DHA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06494488 | Jul 2025 → Aug 2027 expected | hypertriglyceridemia, inherited lipid metabolism disorder | The Miriam Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DHA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06494488 ↗ |
| Modality | Other / unclassified | “omega-3 polyunsaturated fatty acids” NCT06494488 ↗ |
| Route | Oral | “3 gelcaps, three times per day with meals (breakfast, lunch, and dinner).” NCT06494488 ↗ |